Recursion Pharmaceuticals, Inc.
$3.69
▲
1.63%
2026-04-21 09:15:00
www.recursion.com
NMS: RXRX
Explore Recursion Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.95 B
Current Price
$3.69
52W High / Low
$7.18 / $2.8
Stock P/E
—
Book Value
$2.14
Dividend Yield
—
ROCE
-48.86%
ROE
-59.54%
Face Value
—
EPS
$-1.44
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
600
Beta
1.01
Debt / Equity
6.89
Current Ratio
5.5
Quick Ratio
5.5
Forward P/E
-3.85
Price / Sales
23.2
Enterprise Value
$1.06 B
EV / EBITDA
-1.89
EV / Revenue
14.25
Rating
None
Target Price
$6.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 2. | Fractyl Health, Inc. | $0.58 | — | $90.33 M | — | -93.93% | -7.44% | $3.03 / $0.38 | $0.06 |
| 3. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 4. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 5. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 6. | uniQure N.V. | $18.04 | — | $1.07 B | — | -24.65% | -2.07% | $71.5 / $8.73 | $3.19 |
| 7. | KALA BIO, Inc. | $0.2 | — | $185.9 M | — | -88.86% | -388.29% | $20.6 / $0.15 | $-1.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 35.35 M | 4.98 M | 19.1 M | 14.82 M | 4.51 M | — |
| Operating Profit | -108.33 M | -172.2 M | -176.23 M | -191.37 M | -183.77 M | — |
| Net Profit | -108.12 M | -162.25 M | -171.9 M | -202.49 M | -178.91 M | — |
| EPS in Rs | -0.21 | -0.31 | -0.33 | -0.39 | -0.34 | -0.34 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 74.26 M | 58.49 M | 43.88 M | 39.68 M |
| Operating Profit | -648.13 M | -479 M | -350.06 M | -245.73 M |
| Net Profit | -644.76 M | -463.66 M | -328.07 M | -239.48 M |
| EPS in Rs | -1.24 | -0.89 | -0.63 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.47 B | 1.45 B | 653.7 M | 701.29 M |
| Total Liabilities | 343.26 M | 413.82 M | 190.26 M | 215.48 M |
| Equity | 1.13 B | 1.03 B | 463.44 M | 485.81 M |
| Current Assets | 812.85 M | 714.27 M | 438.14 M | 569.81 M |
| Current Liabilities | 147.71 M | 187.47 M | 93.17 M | 100.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -371.81 M | -359.17 M | -287.78 M | -83.52 M |
| Investing CF | -16.87 M | 260.06 M | -10.23 M | 193.25 M |
| Financing CF | 521.53 M | 304.12 M | 140.13 M | 154.34 M |
| Free CF | -380.44 M | -376.22 M | -300.33 M | -120.88 M |
| Capex | -8.63 M | -17.05 M | -12.55 M | -37.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 33.3% | 10.57% | — | — |
| Earnings Growth % | -41.33% | -36.99% | — | — |
| Profit Margin % | -792.75% | -747.71% | -603.5% | — |
| Operating Margin % | -818.98% | -797.84% | -619.26% | — |
| Gross Margin % | 22.65% | 2.94% | -21.66% | — |
| EBITDA Margin % | -729.59% | -701.13% | -573.74% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.